Japanese drugmaker Eisai Co Ltd said on Friday it had priced its newly approved Alzheimer’s disease drug called Leqembi at $26,500 a year. Eisai developed the drug with Biogen Inc.
About the Author
Japanese drugmaker Eisai Co Ltd said on Friday it had priced its newly approved Alzheimer’s disease drug called Leqembi at $26,500 a year. Eisai developed the drug with Biogen Inc.
